ATE500832T1 - Kombination von zd6474 und pemetrexed - Google Patents

Kombination von zd6474 und pemetrexed

Info

Publication number
ATE500832T1
ATE500832T1 AT06820566T AT06820566T ATE500832T1 AT E500832 T1 ATE500832 T1 AT E500832T1 AT 06820566 T AT06820566 T AT 06820566T AT 06820566 T AT06820566 T AT 06820566T AT E500832 T1 ATE500832 T1 AT E500832T1
Authority
AT
Austria
Prior art keywords
pemetrexed
human
combination
antiangiogenic
warm
Prior art date
Application number
AT06820566T
Other languages
English (en)
Inventor
Stephen Wedge
Anderson Ryan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0526121A external-priority patent/GB0526121D0/en
Priority claimed from GB0610706A external-priority patent/GB0610706D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE500832T1 publication Critical patent/ATE500832T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AT06820566T 2005-12-22 2006-12-19 Kombination von zd6474 und pemetrexed ATE500832T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0526121A GB0526121D0 (en) 2005-12-22 2005-12-22 Combination therapy
GB0610706A GB0610706D0 (en) 2006-05-31 2006-05-31 Combination therapy
PCT/GB2006/004750 WO2007071958A2 (en) 2005-12-22 2006-12-19 Combination of zd6474 and pemetrexed

Publications (1)

Publication Number Publication Date
ATE500832T1 true ATE500832T1 (de) 2011-03-15

Family

ID=37814151

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06820566T ATE500832T1 (de) 2005-12-22 2006-12-19 Kombination von zd6474 und pemetrexed

Country Status (19)

Country Link
US (2) US20080269261A1 (de)
EP (1) EP1971338B8 (de)
JP (1) JP5167144B2 (de)
KR (1) KR20080079675A (de)
AT (1) ATE500832T1 (de)
AU (1) AU2006328189B2 (de)
BR (1) BRPI0620140A2 (de)
CA (1) CA2631764A1 (de)
CY (1) CY1111547T1 (de)
DE (1) DE602006020621D1 (de)
DK (1) DK1971338T3 (de)
HR (1) HRP20110360T1 (de)
IL (1) IL191796A0 (de)
NO (1) NO20082567L (de)
NZ (1) NZ568811A (de)
PL (1) PL1971338T3 (de)
PT (1) PT1971338E (de)
SI (1) SI1971338T1 (de)
WO (1) WO2007071958A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
DE602004032310D1 (de) * 2003-02-13 2011-06-01 Astrazeneca Ab Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11
JP2007526886A (ja) * 2003-07-10 2007-09-20 アストラゼネカ アクチボラグ 血管新生および/または血管透過性増大に関連する疾患の処置における、プラチナ系抗腫瘍剤および任意の電離放射線と組み合わせてのキナゾリン誘導体zd6474の使用
GB0318422D0 (en) * 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Zd6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
CA2631764A1 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed
KR20080077678A (ko) * 2005-12-22 2008-08-25 아스트라제네카 아베 Azd2171 및 페메트렉시드의 조합물
WO2008037996A1 (en) * 2006-09-29 2008-04-03 Astrazeneca Ab Combination of zd6474 and bevacizumab for cancer therapy
US20090221615A1 (en) * 2008-02-29 2009-09-03 Guru Reddy Combination anti-cancer agents
RU2627588C2 (ru) 2010-03-08 2017-08-09 Спектрум Фармасьютикалз, Инк. Способы лечения рака с применением ингибитора аутофагии на основе тиоксантона

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1014953B1 (de) * 1997-03-05 2012-04-25 Sugen, Inc. Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US7001911B2 (en) * 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
US6946456B2 (en) * 2000-07-28 2005-09-20 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
AU2003249000B2 (en) * 2002-08-09 2007-04-05 Astrazeneca Ab Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
DE602004032310D1 (de) * 2003-02-13 2011-06-01 Astrazeneca Ab Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11
JP2007526886A (ja) * 2003-07-10 2007-09-20 アストラゼネカ アクチボラグ 血管新生および/または血管透過性増大に関連する疾患の処置における、プラチナ系抗腫瘍剤および任意の電離放射線と組み合わせてのキナゾリン誘導体zd6474の使用
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Zd6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
CA2631764A1 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed
KR20080077678A (ko) * 2005-12-22 2008-08-25 아스트라제네카 아베 Azd2171 및 페메트렉시드의 조합물
WO2008037996A1 (en) * 2006-09-29 2008-04-03 Astrazeneca Ab Combination of zd6474 and bevacizumab for cancer therapy

Also Published As

Publication number Publication date
PL1971338T3 (pl) 2011-07-29
WO2007071958A3 (en) 2008-03-27
NZ568811A (en) 2011-06-30
JP2009520783A (ja) 2009-05-28
IL191796A0 (en) 2008-12-29
EP1971338A2 (de) 2008-09-24
KR20080079675A (ko) 2008-09-01
EP1971338B8 (de) 2011-09-21
NO20082567L (no) 2008-07-31
DE602006020621D1 (de) 2011-04-21
EP1971338B1 (de) 2011-03-09
US20080269261A1 (en) 2008-10-30
AU2006328189B2 (en) 2010-01-21
CA2631764A1 (en) 2007-06-28
DK1971338T3 (da) 2011-05-23
BRPI0620140A2 (pt) 2011-11-01
WO2007071958A2 (en) 2007-06-28
HK1123186A1 (en) 2009-06-12
AU2006328189A1 (en) 2007-06-28
US20110212978A1 (en) 2011-09-01
PT1971338E (pt) 2011-05-09
HRP20110360T1 (hr) 2011-06-30
SI1971338T1 (sl) 2011-06-30
CY1111547T1 (el) 2015-08-05
JP5167144B2 (ja) 2013-03-21

Similar Documents

Publication Publication Date Title
CY1111547T1 (el) Συνδυασμος zd6474 και πεμετρεξεδης
SI1551409T1 (sl) Uporaba kinazolinskega derivata ZD6474, kombiniranega z gemcitabinom in po želji ionizirajočim obsevanjem, pri zdravljenju raka
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
MX2007003505A (es) Combinacion que comprende zd6474 e imatinib.
MXPA05008583A (es) Terapia de combinacion de zd6474 con 5-fu y/o cpt-11.
MX2007005356A (es) Terapia de combinacion que comprende zd6474 y un antiadrogenico.
PL1653964T3 (pl) Skojarzone leczenie raka obejmujące AZD2171 i ZD1839
NO20064755L (no) Kombinasjonsterapi
NO20064754L (no) Kombinasjonsterapi
NO20056171L (no) Kombinasjonsterapi
WO2005092384A3 (en) Combination therapy with azd2171 and a platinum anti-tumour agent
WO2007003933A3 (en) Combination therapy of cancer with azd2171 and gemcitabine

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1971338

Country of ref document: EP